NEW YORK, December 30, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Novo Nordisk A/S (NYSE: NVO), Hospira Inc. (NYSE: HSP), Tesaro, Inc. (NASDAQ: TSRO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Novo Nordisk A/S Research Report
On December 20, 2013, Novo Nordisk A/S (Novo Nordisk) announced that it has filed two separate regulatory approvals for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. Novo Nordisk informed that it has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA). Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, stated, "We believe that liraglutide 3 mg has the potential to make a significant difference in the management of obesity by providing both a sustainable weight loss and an improvement in several obesity-related comorbidities." The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Hospira Inc. Research Report
On December 17, 2013, Hospira Inc. (Hospira) announced that it will present at the upcoming J.P. Morgan 32nd Annual Healthcare Conference in San Francisco on Wednesday, January 15, 2014 at 10:30 a.m. PT, which will be accessible through a live webcast via the investor relations section of Hospira's website. Hospira also informed that a replay will be available on its website approximately 24 hours after the live presentation for 30 days. The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Tesaro, Inc. Research Report
On December 23, 2013, Tesaro, Inc. (Tesaro) announced top-line results for two Phase 3 trials of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). According to the Company, the primary endpoint was successfully achieved in each trial and preparations are ongoing in support of a New Drug Application (NDA) submission for oral rolapitant to the US Food and Drug Administration (FDA). Mary Lynne Hedley, Ph.D., Tesaro President, commented, "Despite the availability of preventative therapies and established treatment guidelines for CINV, a significant number of cancer patients still suffer from the debilitating side effects of delayed nausea and vomiting." Hedley added, "We are enthusiastic about the potential for this product candidate, with a profile that may include an extended half-life, convenient, single-dose oral and intravenous formulations and a lack of CYP3A4-mediated drug interactions." The Full Research Report on Tesaro, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Alnylam Pharmaceuticals, Inc. Research Report
On December 16, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin (TTR) gene in development for the treatment of TTR-mediated amyloidosis (ATTR). Alnylam reported that the Phase II trial is aimed at evaluating the tolerability and preliminary clinical activity of ALN-TTRsc in TTR cardiac amyloidosis patients with familial amyloidotic cardiomyopathy (FAC) - which is caused by autosomal dominant mutations in the TTR gene, or senile systemic amyloidosis (SSA) - which is caused by idiopathic accumulation of wild-type TTR in the heart. The Company expects to present data from the Phase II trial in late 2014, and assuming positive results, begin a Phase III trial in TTR cardiac amyloidosis patients by the end of 2014. The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Sanofi Research Report
On December 19, 2013, Sanofi and Regeneron Pharmaceuticals, Inc. announced an innovative collaboration with the American College of Cardiology (ACC) focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), which is known to contribute to circulating lowdensity
lipoprotein cholesterol (LDL-C) levels. Commenting on this collaboration, Jay Edelberg, M.D., Ph.D. Vice President, PCSK9 Development and Launch Unit, Sanofi, said, "Through this collaboration, we hope to provide better access to our Phase 3 ODYSSEY OUTCOMES Trial. This is the first time that ACC's PINNACLE Registry will be used for clinical trial recruitment, and we believe this novel approach will help trial sites meet and hopefully exceed their recruitment goals." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner